This has a chart similar to NTRO in being that it has slowly climbed down and now bottomed and is quite volatile... Havent gone deep at all into looking at this, but any thoughts on this would be appreciated... It jumped 59% today... Going up n down from .0024 to a high of .0042 and closing at .0035.


News came out after closing.... The ask is up to .0039... Expect a higher open tomorrow than close today...

https://research.ameritrade.com/inve...100-159u2638-1

Just thought that I would share what a typical pinkie IGNT really is.

1 for 3,000 Reverse Split in January 2009.

Since then:

Outstanding Shares

268,675,075 as of May 13, 2009

520,435,723 as of May 27, 2009

1,283,038,135 as of Jun 23, 2009

You're math is correct. That's a BILLION new shares issued.

__________________
Learn Pincher Plays and the Basics of Technical Analysis. I've learned a lot from Greencat and CC and a portion of all sales go back to SMC.

"Always bear in mind that your own resolution to success is more important than any other one thing." - Abraham Lincoln

"The heights by great men reached and kept, were not obtained by sudden flight. But they, while their companions slept, were toiling upward in the night." - Longfellow

a cigarette thats smoke and tabacco free no more second hand smoke that says it all
its at a stand still right now .
RSI is comfortable in the 30s
the signal is at.041
high res is is at 0.24
the low is 0.05

Ingen Cuts Manufacturing Costs and Increases Its Margins
Ingen Cuts Manufacturing Costs and Increases Its Margins
Oct. 14, 2009 (GlobeNewswire) --
YUCAIPA, Calif., Oct. 14, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading Global Medical Device manufacturer focused in the $4 billion Respiratory Market for the growing ageing and emerging markets for Home (DME), Hospital and Aviation Industries, announced today that the company has received a proposal from a leading manufacturer to help reduce production costs and material costs by 50% for the manufacture of the Oxyview and the Oxyview Nasal Cannula.

As a part of improving product quality in large production, and reducing material and production costs to be more competitive in the respiratory marketplace, the company has received a proposal from a leading respiratory equipment manufacturer based in Pomona-California. The company CEO, and some of the management staff received a proposal on Wednesday last week to manufacture both the Oxyview and the Oxyview Nasal Cannula at 50% of the original costs from its current manufacturer and supplier. On Friday last week, they had a meeting in Pomona with the new manufacturer to discuss the new manufacturing and distribution of Oxyview and the new Oxyview Nasal Cannula.

"Now that we are selling our respiratory products, and sales have escalated, we must reduce our cost of goods sold in order to increase our profit margins and decrease the costs to our dealers and buyers. This change will give the company a stronger foot-hold in the market. We have a proprietary product and there is nothing in the marketplace that can compete with our device. We have gained support for all sectors of our industry, inclusive of leading respiratory equipment manufacturers, clinical foundations and more important, our shareholders," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.

Ingen Technologies,Inc. - Home

About Ingen:

Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

CONTACT: Ingen Technologies, Inc.
Jeff Morgan
909-790-7180
info@ingen-tech.com
Ingen Technologies,Inc. - Home

yeah i know i screwed up with the symbols yesterday sorry guys just had a lot going on . anyway im back on ignt vol a little low but i believe its gonna start to go again

Volume way up from this morning. Should finish strong. Staying with it.


Ingen Technologies, Inc. develops, markets, and distributes medical technologies and products with applications in the respiratory device and medical diagnostics market primarily in the United States. It offers BAFI line of products, its flagship product, which are wireless digital low gas warning system for pressurized gas cylinders. These products include Oxyview and OxyAlert, which provides the respiratory clinicians, including pulmonologists, respiratory therapists, and patient care technicians a medical product that offers assurance and safety to home oxygen patients and hospitalized patients, while monitoring oxygen flow during oxygen therapy; and GasAlert, which monitors and detects gas flow for home appliances, such as ovens, washer, dryer, refrigerator, and outdoor plumbed barbeques. The BAFI line of products has applications in the medical industry, home consumer, residential development industry, safety and protection (fire and police), aircraft industry, and the recreational vehicle industry. The company also offers a Secure Balance product, a private-label product that includes a vestibular function testing system and balance therapy system for physicians. Ingen Technologies was founded in 1999 and is based in Yucaipa, California.

IGNT

is in a buyers market right now its a low risk with the potential to make a quick profit and with the possibility of news breaking later in the day it should start to move with a very good chance to heat up. bb's adding, next week will be big imo.

Ingen Brings Aboard Leading OEM Partner for Australia


Medical Industries Australia Pty LTD Signs OEM Contract

YUCAIPA, Calif., Oct 23, 2009 (GlobeNewswire via COMTEX) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries announced today that Medical Industries Australia has signed an OEM contract with Ingen.
Medical Industries Australia is a leading provider of sterile and non-sterile medical products, training and maintenance services, and provides high quality products and services to the Australian healthcare sector and has been supplying distributors and resellers, public and private hospitals, government departments, private clinics, aged care facilities and medical surgeries for more than 20 years.

In Australia, under the national Medicare health scheme, all interstitial lung disease and COPD patients who require oxygen therapy, are provided with a 5 liter/min oxygen concentrator at no cost, this includes a free Oxygen tubing & nasal cannula each month. State Government funded, the concentrators and consumables suppliers are selected by tender, usually on a 3+1 year arrangement.

In the case of new or innovative devices, such as Ingen's Oxyview Nasal Cannula, they fall outside the state tender and can be offered to public government-funded hospitals for trial and evaluation and if accepted, purchased by the various respiratory departments to be used by their patients. Approximately 1,000 COPD patients, each day, occupy a public hospital bed in Australia (at a cost of $580 per day). In many cases it's due to an exacerbation requiring a respiratory investigative review with new titration and oxygen therapy needs established. Approximately 30,000 patients use Oxygen concentrators on a daily basis.

"I look forward to working with Angus Taylor, CEO of Medical Industries Australia. He has already mentioned strong interest from local acute public hospitals in Sydney. We will commence product shipments upon completion of our ISO Certification and CE Mark expected in late December-2009," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.

Medical Industries Australia > Home

Ingen Technologies,Inc. - Home

About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

This news release was distributed by GlobeNewswire, GlobeNewswire - Press Release Distribution - EDGAR Filings - Video News Releases

SOURCE: Ingen Technologies, Inc.


By Staff

CONTACT: CONTACT: Ingen Technologies, Inc.
Jeff Morgan
909-790-7180
Ingen Technologies,Inc. - Home

(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.
-0-

INDUSTRY KEYWORD: Healthcare & Medical Services
SUBJECT CODE: MEDICAL
Business Contracts

Ingen Reports First Quarter Sales Increase
With Gross Profits Increase and a 63% Gross Margin of Sales

Press Release
Source: Ingen Technologies, Inc.
On 8:15 am EDT, Monday October 26, 2009


YUCAIPA, Calif., Oct. 26, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries announced today that the company has reported an increase in first quarter sales for 2009 as compared to the same quarter in 2008. Gross profits represented 63% gross margins.



Ingen reported gross sales of $106,483 in the quarter ended August 31, 2009. This represented an increase from sales of $987 in the quarter ended August 31, 2008. The sales were further sparked by the introduction of an "all-in-one" Oxyview Nasal Cannula unit that includes a cannula with the Oxyview flow meter included. Additional capital also enabled the company to increase its advertising and marketing of the Oxyview products. Ingen anticipates that sales of Oxyview will increase from the current quarter's sales as the company expands its sales channels. The total cost of sales was $38,804 in the quarter ended August 31, 2009 and the gross profit was $67,679 (a gross margin of 63.6%).



"We are seeing the initial results of the introduction of our Oxyview Nasal Cannula. There is still hard work ahead of us, and our management is focused on distribution and sales. Our immediate focus being ISO certification and CE Mark requirements that we will complete in late December-2009. Between now and then we are closing distribution for export of our products, and reorganizing our domestic distribution. The home oxygen patients are the bulk of our sales at this time, and this is a good indication that they want and need this product. We expect an increased response for our new Oxyview Nasal Cannula upon its introduction to the annual Chest Physicians meeting at the end of this month, along with Medical and Arab Health conventions in the near future. Targeting these respiratory physicians, management and home oxygen suppliers will increase sales significantly," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board

Ingen CEO Live Radio Interview Today With The Money Channel
Increased Sales, Margins and Profits Bring Bright Future for Shareholders

Press Release
Source: Ingen Technologies, Inc.
On 12:38 pm EDT, Tuesday October 27, 2009
Buzz up! Print
Companies:Ingen Technologies, Inc.

YUCAIPA, Calif., Oct. 27, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries announced today that the CEO, Scott Sand, discussed increased profits, margins and sales at 11:34am eastern daylight time today on The Money Channel's American Scene Radio with host Steve Crowley.


Related Quotes
Symbol Price Change
IGNT.PK 0.00 0.00


{"s" : "ignt.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""}
"The company sales for first quarter had increased more than a 100 times compared to last year due to the acceptance of the product by the home oxygen patients and respiratory medical market. Margins of sales were slightly better than 63%. The future of this company for any investor, compared to other companies in the market place, is strong and steady," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.



The company introduced a new revolutionary product into the medical market this past June-2009, called the Oxyview Nasal Cannula. Oxyview, the World's First Patient In-Line Oxygen Flow-Meter, and Oxyview Nasal Cannula, the World's First Cannula with a built-in oxygen flow meter is another innovative respiratory product manufactured in the USA by Ingen Technologies; providing more confidence and assurance to patients who require home oxygen therapy or supplemental oxygen.



Welcome



Medco Forum - About Us



American College of Chest Physicians



Welcome to the COPD Digest!



Senior Living : Retirement : Elderly Health : Today's Senior Magazine



MEDICA 2009 - Messe Düsseldorf North America



index



Ingen Technologies,Inc. - Home



About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the US, and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.



The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.



Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.






Contact:
Ingen Technologies, Inc.Jeff Morgan909-790-7180 Ingen Technologies,Inc. - Home